Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

September 30, 2010 09:00 ET

Theralase Receives Popular Mechanics Magazine "2010 Breakthrough Award" for the Company's Innovative Cancer Therapy Technology

TORONTO, ONTARIO--(Marketwire - Sept. 30, 2010) - Theralase Technologies Inc. (TSX VENTURE:TLT) has been awarded a 2010 Breakthrough Award by Popular Mechanics Magazine for its work with lasers in the destruction of cancer cells.

Theralase Technologies Inc. President and CEO, Roger Dumoulin-White joins Karen Brewer and Brenda Winkel of Virginia Tech to receive the award at the Hearst Tower in New York on October 5, 2010. Popular Mechanics Magazine's "Breakthrough Awards" is honouring the year's most impressive advances in science and technology.

Dumoulin-White stated, "It is humbling to be acknowledged by such a prestigious magazine as Popular Mechanics, a magazine, which portrayed technology that I was always awe struck with as a child. We believe our work with patented Theralase lasers and PDCs for the destruction of cancer cells is truly groundbreaking and I speak on behalf of the entire company to say we are very excited to receive this award. We plan to continue our work toward commercializing this technology for the real and tangible benefit of all."

Lothar Lilge, Ph.D., the principal investigator of the PDCs, a published expert on PDCs and a leading researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network stated, "We are currently awaiting the final approval to commence testing the PDCs in a live small animal model to evaluate toxicity. In vitro, the lead PDCs have demonstrated low reaction without the presence of light, proving the safety of the compounds and a moderate to high ability to destroy cancer cells when subjected to light, indicating their innate ability to destroy cancer cells. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid core tumours, such as: breast and prostate cancers. In conjunction with Virginia Tech, we will optimize the lead compounds for cancer cell destruction. Successful completion of a small animal pre clinical study and the knowledge accumulated from it in regards to PDC light dose interactions, such as toxicology, safety and efficacy, will pave the way for companion animal treatments and early human trials under FDA Phase 1, as early as 2011."

Popular Mechanics, published monthly by Hearst Magazines, inspires, instructs and influences almost 9 million curious readers. Their mindset—the desire to understand how the world works—drives them to explore, experiment with and experience a wide range of interests. The Award winners will be highlighted in the November issue of Popular Mechanics, on newsstands Oct. 12, with winner profiles currently online at www.popularmechanics.com/breakthrough10.

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. 

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information